TCON TRACON Pharmaceuticals, Inc.

3.95
-0.05  -1.25%
Previous Close 4.00
Open 3.95
Price To book 2.94
Market Cap 51.61M
Shares 13,065,000
Volume 14,284
Short Ratio 1.75
Av. Daily Volume 87,029

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 dosing initiated May 2016 with data due early 2018.
TRC105 and Nexavar
Hepatocellular carcinoma (HCC) - cancer
Phase 2 initiated Dec 2014. Phase 2 data top-line PFS data due 2H 2017.
TRC105 and Inlyta
Renal Cell Carcinoma (RCC) - cancer
Phase 2 data released February 9, 2017 - primary endpoint not met.
TRC105 and Avastin
Glioblastoma - cancer
Phase 2 planned for 2016. Data due 4Q 2017.
TRC105
Gestational Trophoblastic Neoplasia cancer
Phase 2 trial initiated January 2016.
TRC102 and Temodar
Glioblastoma - cancer
Phase 2 initiated October 2015. Data are due in 2017.
TRC102
Mesothelioma cancer
Phase 3 dosage of first patient announced February 16, 2017.
TRC105 (TAPPAS)
Angiosarcoma cancer
Phase 2 data due late 2016 according to 10Q filed November 2016. As of January 9, 2016, data have not been released and no mention of the trial was made in its January 9 presentation.
TRC105
Soft tissue sarcomas

Latest News

  1. TRACON to Report Fourth Quarter and Full Year 2016 Company Highlights and Financial Results on February 28, 2017
  2. TRACON Pharmaceuticals Announces First Patient Dosed in Phase 3 TAPPAS Trial of TRC105 in Angiosarcoma
  3. Tracon Pharma Tanks on Brain Cancer Drug Failure
  4. TRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  5. TRACON Pharmaceuticals Announces Top-line Results from NCI-Sponsored Phase 2 Trial of TRC105 in Recurrent Glioblastoma
  6. TRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
  7. TRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fin
  8. TRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclos
  9. TRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  10. Tuesday’s Biggest Biotech and Pharma Moves
  11. TRACON Pharmaceuticals Receives Special Protocol Assessment (SPA) Agreement from FDA for Phase 3 Clinical Trial of TRC105 in Angiosarcoma
  12. TRACON Pharmaceuticals Receives Special Protocol Assessment (SPA) Agreement from FDA for Phase 3 Clinical Trial of TRC105 in Angiosarcoma
  13. ETFs with exposure to TRACON Pharmaceuticals, Inc. : December 22, 2016
  14. Coverage initiated on Tracon Pharmaceuticals by Jefferies
  15. TRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and
  16. TRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and
  17. ETFs with exposure to TRACON Pharmaceuticals, Inc. : December 9, 2016
  18. TRACON Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
  19. TRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  20. TRACON Pharmaceuticals Announces Pricing of Public Offering of Common Stock